Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer

Journal of Pathology

Volumn 242, Issue 2, 2017, Pages 140-151

  Rynne Vidal, Angela ^a,b   Au Yeung, Chi Lam ^b   Jiménez Heffernan, José A ^c   Pérez Lozano, María Luisa ^a   Cremades Jimeno, Lucía ^a   Bárcena, Carmen ^d   Cristóbal García, Ignacio ^e   Fernández Chacón, Concepción ^e   Yeung, Tsz Lun ^b   Mok, Samuel C ^b   Sandoval, Pilar ^a   López Cabrera, Manuel ^a  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e Hospital Sanitas La Zarzuela   (Spain)

Author keywords

ascites; carcinoma associated fibroblasts; mesothelial to mesenchymal transition; ovarian cancer; peritoneal metastasis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALRETININ; EARLY GROWTH RESPONSE FACTOR 1; GREMLIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; ONCOPROTEIN; RNA; SCATTER FACTOR; SMAD3 PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; SMAD3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES FLUID; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CARCINOMATOUS PERITONITIS; CELL ISOLATION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MESENCHYME CELL; MESOTHELIAL TO MESENCHYMAL TRANSITION; MESOTHELIUM CELL; MOUSE; MYOFIBROBLAST; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; STEM CELL NICHE; TARGET CELL; TUMOR XENOGRAFT; ANIMAL; ASCITES; CARCINOMA; COMPLICATION; DISEASE MODEL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROBLAST; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; SECONDARY; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ANIMALS; ASCITES; ASCITIC FLUID; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROBLASTS; HUMANS; MICE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SEQUENCE ANALYSIS, RNA; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 85017390748     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4889     Document Type: Article

References (51)

1. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006; 7: 925–934.
2. Della Pepa C, Tonini G, Pisano C. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer 2015; 34: 17–27.
3. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374: 1371–1382.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
5. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000; 20(suppl 3): S5–S96.
6. Sandoval P, Jiménez-Heffernan JA, Rynne-Vidal A, et al. Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol 2013; 231: 517–531.
7. Rynne-Vidal A, Jiménez-Heffernan J, Fernández-Chacón C, et al. The mesothelial origin of carcinoma associated-fibroblasts in peritoneal metastasis. Cancers 2015; 7: 1994–2011.
8. Yanez-Mo M, Lara-Pezzi E, Selgas R, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403–413.
9. López-Cabrera M. Mesenchymal conversion of mesothelial cells is a key event in the pathophysiology of the peritoneum during peritoneal dialysis. Adv Med 2014; 2014: 1–17.
10. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013; 228: 1651–1657.
11. Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci 2012; 103: 626–631.
12. Nakamura M, Ono YJ, Kanemura M, et al. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial–mesenchymal transition of the peritoneum. Gynecol Oncol 2015; 139: 345–354.
13. Kenny HA, Chiang C-Y, White EA, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 2014; 124: 4614–4628.
14. Matte I, Lane D, Laplante C, et al. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2012; 2: 566–580.
15. Matte I, Lane D, Bachvarov D, et al. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 2014; 14: 288.
16. Loureiro J, Aguilera A, Selgas R, et al. Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol 2011; 22: 1682–1695.
17. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59–69.
18. Siddique I, Curran SP, Ghayur A, et al. Gremlin promotes peritoneal membrane injury in an experimental mouse model and is associated with increased solute transport in peritoneal dialysis patients. Am J Pathol 2014; 184: 2976–2984.
19. Patel P, Sekiguchi Y, Oh K-H, et al. Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. Kidney Int 2010; 77: 319–328.
20. Li Y, Wang J, Asahina K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial–mesenchymal transition in liver injury. Proc Natl Acad Sci U S A 2013; 110: 2324–2329.
21. Luo L, Liu H, Dong Z, et al. Small interfering RNA targeting ILK inhibits EMT in human peritoneal mesothelial cells through phosphorylation of GSK-3β. Mol Med Report 2014; 10: 137–144.
22. Vi L, de Lasa C, DiGuglielmo GM, et al. Integrin-linked kinase is required for TGF-β1 induction of dermal myofibroblast differentiation. J Invest Dermatol 2010; 131: 586–593.
23. Razani B, Zhang XL, Bitzer M, et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 2001; 276: 6727–6738.
24. Strippoli R, Loureiro J, Moreno V, et al. Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial–mesenchymal transition and fibrosis during peritoneal dialysis. EMBO Mol Med 2015; 7: 102–123.
25. Larriba MJ, de Herreros AG, Muñoz A. Vitamin D and the epithelial to mesenchymal transition. Stem Cells Int 2016; 2016: 1–12.
26. Zhong Y-C, Zhang T, Di W, et al. Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial–mesenchymal transition. J Gynecol Oncol 2013; 24: 265–272.
27. Strippoli R, Benedicto I, Foronda M, et al. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J Cell Sci 2010; 123: 4321–4331.
28. Sandoval P, Loureiro J, González-Mateo G, et al. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Lab Invest 2010; 90: 1517–1532.
29. González-Mateo GT, Fernández-Millara V, Bellón T, et al. Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. PLoS ONE 2014; 9: e108477.
30. Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol 2014; 25: 61–68.
31. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161–174.
32. Al-Alem L, Curry TEJ. Ovarian cancer: involvement of the matrix metalloproteinases. Reproduction 2015; 150: R55–R64.
33. Margetts PJ, Bonniaud P, Liu L, et al. Transient overexpression of TGF-b1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16: 425–436.
34. Kolomeyevskaya N, Eng KH, Khan ANH, et al. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol 2015; 138: 352–357.
35. Stadlmann S, Feichtinger H, Mikuz G, et al. Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids – evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium. Int J Gynecol Cancer 2014; 24: 192–200.
36. Catar R, Witowski J, Wagner P, et al. The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation. Kidney Int 2013; 84: 1119–1128.
37. Offner FA, Obrist P, Stadlmann S, et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995; 7: 542–547.
38. Agarwal A, Tressel SL, Kaimal R, et al. Identification of a metalloprotease–chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 2010; 70: 5880–5890.
39. Chen S-F, Nieh S, Jao S-W, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 2013; 231: 180–189.
40. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and −2. Cold Spring Harb Perspect Med 2012; 2: a006627.
41. Lin X-D, Chen S-Q, Qi Y-L, et al. Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J Surg Oncol 2012; 106: 94–100.
42. Loureiro J, Schilte M, Aguilera A, et al. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrol Dial Transplant 2010; 25: 1098–1108.
43. Kataoka F, Tsuda H, Arao T, et al. EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy. Genes Chromosomes Cancer 2012; 51: 300–312.
44. Sandoval P, Jiménez-Heffernan JA, Guerra-Azcona G, et al. Mesothelial-to-mesenchymal transition in the pathogenesis of post-surgical peritoneal adhesions. J Pathol 2016; 239: 48–59.
45. Miao Z-F, Zhao T-T, Wang Z-N, et al. Transforming growth factor-beta1 signaling blockade attenuates gastric cancer cell-induced peritoneal mesothelial cell fibrosis and alleviates peritoneal dissemination both in vitro and in vivo. Tumour Biol 2013; 35: 3575–3583.
46. Nilsson EE, Skinner MK. Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod Biomed Online 2002; 5: 254–258.
47. Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 2012; 22: 571–584.
48. Antony ML, Nair R, Sebastian P, et al. Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors. J Cancer Res Clin Oncol 2010; 136: 351–361.
49. Chan MW, Huang Y-W, Hartman-Frey C, et al. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 2008; 10: 908–919.
50. Dunfield LD, Dwyer EJC, Nachtigal MW. TGF beta-induced Smad signaling remains intact in primary human ovarian cancer cells. Endocrinology 2002; 143: 1174–1181.
51. Do T-V, Kubba LA, Du H, et al. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 2008; 6: 695–705.